How Analysts Feel About Ascendis Pharma A/S (ASND) After Today’s Huge Increase?

April 17, 2018 - By Michael Collier

The stock of Ascendis Pharma A/S (NASDAQ:ASND) is a huge mover today! The stock increased 6.25% or $3.91 during the last trading session, reaching $66.42. About 157,091 shares traded. Ascendis Pharma A/S (NASDAQ:ASND) has risen 130.09% since April 17, 2017 and is uptrending. It has outperformed by 118.54% the S&P500.
The move comes after 8 months positive chart setup for the $2.76 billion company. It was reported on Apr, 17 by Barchart.com. We have $72.40 PT which if reached, will make NASDAQ:ASND worth $248.22 million more.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

Among 4 analysts covering Ascendis Pharma A\/S (NASDAQ:ASND), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ascendis Pharma A\/S had 11 analyst reports since November 17, 2017 according to SRatingsIntel. Credit Suisse maintained Ascendis Pharma A/S (NASDAQ:ASND) rating on Thursday, February 22. Credit Suisse has “Buy” rating and $50.0 target. The stock has “Buy” rating by Wedbush on Friday, January 5. As per Wednesday, January 17, the company rating was maintained by J.P. Morgan. The rating was maintained by Bank of America with “Buy” on Friday, November 17. The company was maintained on Monday, February 26 by Wedbush. Wedbush maintained the shares of ASND in report on Wednesday, April 4 with “Buy” rating. On Tuesday, March 20 the stock rating was maintained by Credit Suisse with “Outperform”. Wedbush maintained Ascendis Pharma A/S (NASDAQ:ASND) rating on Monday, March 19. Wedbush has “Buy” rating and $67.0 target. The stock has “Buy” rating by Wedbush on Tuesday, February 6. The company was maintained on Thursday, January 25 by Bank of America.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $2.76 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.